The federal judge overseeing consolidated litigation over side effect warnings on Ozempic and similar drugs on Wednesday appointed Morgan & Morgan PA, Seeger Weiss LLP, Wagstaff & Cartmell LLP, and Motley Rice to be lead counsel for the plaintiffs.
Judge Gene E.K. Pratter of the US District Court for the Eastern District of Pennsylvania previously appointed attorneys form Levin Papantonio Rafferty Proctor Buchanan O’Brien Barr & Mougey PA, Pogust Goodhead, and Johnson Becker PLLC, among others, to the plaintiffs’ committee.
- Dozens of lawsuits have accused
Novo Nordisk A/S , the maker of blockbuster diabetes drug Ozempic, and other pharmaceutical companies of downplaying severe gastrointestinal side effects from medications classified as glucagon-like peptide-1 receptor agonists - Ozempic was originally formulated as a diabetes treatment that regulated blood sugar levels through slowing the digestive system down; the drug’s weight loss side effects quickly caused a surge in demand and led to the development of Wegovy
- Lawsuits against
Eli Lilly & Co. over its Mounjaro and Trulicity are also part of the litigation
Novo Nordisk is represented by DLA Piper. Eli Lilly is represented by Welsh & Recker PC, Kirkland & Ellis LLP, and Redgrave LLP.
The case is In re Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Prods. Liab. Litig., E.D. Pa., No. 2:24-md-03094, 5/8/24.
To contact the reporter on this story:
To contact the editor responsible for this story: